Abbott Laboratories
Abbott Laboratories
Pharmavitae Profile
| Publication Date | December 2007 |
| Publisher | Datamonitor |
| Product Type | Report |
| Pages | 169 |
| ISBN Number | not applicable |
| Product Code | DAT01112 |
Price
£1,980.00
approximately: $2,998 | €2,210
approximately: $2,998 | €2,210
print £2,010 ($3,043 | €2,243)
Order above formats by FAX
Summary
Introduction
This analysis examines the historical and forecast performance for Abbott in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
- Benchmark Abbott's performance against key rivals in the ethical pharmaceutical sector
- See how Abbott's performance out to 2012 will be hampered by the termination of its deal with Boehringer Ingelheim
- Learn how the company will look to Humira and a range of dyslipidemia drugs to counteract the sales it will lose to a raft of patent expiries
Contents
- Introduction
- This Analysis Examines The Historical And Forecast Performance For Abbott In The Ethical Pharmaceutical Sector. The Profile Encompasses Global Company Strategy, Portfolio And Pipeline Analysis And Assessment Of Financial Performance, With 1-6 Year Sales Forecasts For Key Drugs. An Interactive Forecasting And Analysis Tool Provides Continually Updated Quantitative And Qualitative Information.
- Scope
- Highlights
- Reasons To Purchase
- Benchmark Abbott's Performance Against Key Rivals In The Ethical Pharmaceutical Sector See How Abbott's Performance Out To 2012 Will Be Hampered By The Termination Of Its Deal With Boehringer Ingelheim Learn How The Company Will Look To Humira And A Range Of Dyslipidemia Drugs To Counteract The Sales It Will Lose To A Raft Of Patent Expiries.
